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Abstract 
A recent revision to the European Medical Device Directive (MDD) 2007/47/EC made fourteen 
amendments to the original directive (93/42/EEC). A number of these changes directly affect the de-
velopment of software for use in healthcare. The most significant change in relation to medical device 
software development is that standalone software is now seen as an active medical device and should 
be developed following state of the art medical device software development processes. State of the 
art medical device software processes is understood within the industry as developing software in 
accordance with IEC 62304 and standards that are aligned with it. This paper identifies how changes 
to the MDD affect medical device software development companies and recommendations are made 
as to how medical device software development companies can conform to the latest regulatory re-
quirements. Additionally, the paper provides an overview of how Medi SPICE is currently being devel-
oped to provide organisations with a single point of reference for the practices that should be imple-
mented in order to produce regulatory compliant medical device software. 
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1 Introduction 
Today the role and importance that software plays in the provision of healthcare continues to grow [1].  
This has resulted in a substantial increase in the functionality, complexity and reliance on software 
components in medical devices [2]. As this reliance on software is increasing, incidents involving soft-
ware failures in medical devices are brought to the fore.  These include incidents such as Therac-25 
[3] and the over exposure of Panamanian Teletherapy patients [4]. To reduce the potential risk a med-
ical device poses to patient’s safety, regulatory bodies enforce regulations that medical device manu-
facturers must conform to. 
   All medical devices used within the European Union (EU) must conform to the current MDD 
to achieve the CE conformance mark. The MDD revision  (2007/47/EC) [5], amends European direc-
tives MDD (93/42/EEC) [6], AIMD (90/385/EEC) [7] and the Biocides Directive (98/8/EC) [8, 9]  .The 
revision to the MDD (2007/47/EC) covers all areas relevant to medical devices including risk and 
quality management. This latest amendment allows for standalone software to be used as an active 
medical device. With this amendment, incidents involving medical devices such as Therac-25 become 
more relevant, as now software may be the only element in a medical device subject to conformance 
requirements.  
 Consequently methods used to ensure that software is safe and fit for purpose must be re-
viewed. A number of benefits can be gained by manufacturers employing Software Process Improve-
ment (SPI) techniques, one of which is a reduction in software faults that could potentially result in 
device recalls [10]. SPI is a continuous cycle of performing an assessment, implementing the recom-
mendations of the assessment and restarting the cycle [9]. This process of continuous assessment 
and improvement can help reduce the amount of defective software being developed. Essentially the 
safety of medical device software is determined through the software processes followed during de-
velopment [11]. 
 IEC 62304:2006 [12] is a harmonised standard as part of the MDD. IEC 62304 contains a 
number of processes for medical device software development which organisations are recommended 
to follow in order to implement medical device software best practices and to streamline the process of 
achieving regulatory approval.   As IEC 62304 is a software development standard it does not provide 
guidance on system level activities. As a result, IEC 62304 hands off the system processes to aligned 
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standards such as ISO 13485:2003 [13], IEC 60601-1:2010 [14], IEC 61010-1:2010 [15], ISO/IEC 
90003:2004 [16], IEC 61508-3:2010 [17], ISO 14971:2009 [18], ISO/IEC 12207:1995 [19] AMD1 [20] 
and AMD2 [21],and ISO/IEC 15288:2008 [22] [12].  The relationship between these standards and the 
EU medical device regulations is shown in table 1. 
 
European  
Regulations 
Active Implantable Medical Device (AIMD Directive 90/385/EEC, Medical Device 
Directive 93/42/EEC (Amendment 2007/47/EC), Biocides Directive 98/8/EC 
Applicable 
Standards 
ISO 13485 – Quality Management Systems, IEC 62304 – Software Lifecycle 
Processes, IEC 60601-1 Medical Electrical Equipment, IEC 61010-1* – Safety 
Requirements for Electrical Equipment, ISO 15288* – Systems and Software 
Engineering, ISO 90003* -  Software Engineering, ISO 12207* – Systems and 
Software Engineering, ISO 14971 – Application of Risk Management 
*Not Specific to the development of medical devices 
Technical  
Reports IEC TR 80002-1 
Table 1: European Regulations, Applicable Standards and Technical Reports applicable to the 
development of medical devices 
 
 
As part of this research the changes to the MDD that have an impact on the development of medical 
device software are identified and explained. Also, recommendations are made as to how medical 
device software development organisations can conform to this latest MDD amendment and to other 
important international standards.  
The remainder of this paper is structured as follows; section 2 examines the revision to the 
MDD and highlights what this means with respect to medical device software development. This will 
include particular reference to the development of standalone software as an active medical device. In 
section 3, we discuss the existing standards that are appropriate to the development of medical devic-
es with emphasis on satisfying the requirements of the MDD (2007/47/EC). In section 4, we discuss 
the importance of SPI techniques and recommend a specific SPI model (Medi SPICE) to follow in 
order to achieve compliance with medical device software regulations. Section 5, contains the conclu-
sions from this research. 
2 European Medical Device Directive Amendment 2007/47/EC 
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The recent MDD [5] revision has made a number of amendments to previous directives i.e. [6, 7, 23]. 
The MDD revision came into force on March 21st 2010. In total there are fourteen changes introduced 
within the revised MDD [24]. There are three areas within the amendment of the revised MDD with 
important significance to medical device software development: 
 
¾ Standalone Software as an active medical device; 
¾ Validation of software as an active medical device; 
¾ Outsourced Design and Manufacturing; 
2.1 Standalone Software as an Active Medical Device 
Prior to the release of the revised MDD provision had been made within the MDD (93/42/EEC) for 
software to be used as a component of a medical device. However, the revised MDD Article 1 Section 
2 makes explicit reference to software (used alone or in combination) being a medical device. 
“any instrument, apparatus, appliance, software, material or other article, whether used alone or in 
combination, including the software intended by its manufacturer to be used specifically for diagnostic 
and/or therapeutic purposes and necessary for its proper application” 
To accompany this change provision has also been made for standalone software to be used as an 
active medical device. Within the revised MDD Annex IX Section 1.4 amendment M5 states: 
“Stand-alone software is considered to be an active medical device” 
This can be difficult to understand particularly in relation to when software is or is not a medical de-
vice. An example of software as an active medical device is a software package which is used to cal-
culate treatment doses for oncology treatment devices. A caveat has also been included into the re-
vised MDD to avoid ambiguity in determining if a software package is a medical device. 
“software for general purpose when used in a healthcare setting is not a medical device” 
This caveat provides some clarity surrounding particular software used in healthcare. The European 
Commission released a MEDDEV guidance document in January 2012 [25]. This document provides 
clarity as to which types of software used in healthcare meet the criteria of being standalone software 
which is subject to regulatory conformance. 
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2.2 Software Validation 
As standalone software is now classified as an active medical device under the revised MDD, safe-
guards must be put in place to ensure that such software is safe and fit for purpose. To ensure this the 
MDD Annex I Section 12.1a (amendment M5) states; 
“For devices which incorporate software or which are medical software in themselves, the software 
must be validated according to the state of the art taking into account the principles of development 
lifecycle, risk management, validation and verification.” 
“State of the Art” is used here to mean what is generally accepted as good practice. Since this re-
quirement was introduced, software development companies must now validate software whether 
integrated or standalone, regardless of device class. IEC 62304 is aligned with standards: ISO 13485, 
IEC 62366 [26], EN 60601 and ISO 14971; and is harmonised under the MDD. Therefore, medical 
device software organisations adopting IEC 62304 together with the standards it is aligned with are 
considered to be following “state of the art” practices in relation to medical device software develop-
ment and maintenance.   
2.3 Outsourced Design and Manufacturing 
Outsourcing is becoming more and more common place in all industries This is particularly relevant 
with regard to software development which due to the popularity of outsourcing can be now be con-
sidered a globally sourced commodity [27, 28]. As part of the latest MDD amendment, should a device 
manufacturer outsource any part of the design or manufacturing process, then the manufacturer must 
be able to demonstrate that adequate controls have been put in place to ensure the supplier is fully 
utilising a quality management system. Currently, there is no internationally accepted assessment 
model utilised for medical device manufacturers when assessing the ability of a medical device soft-
ware supplier to develop software in a regulatory compliant manner. However, in Section 4, we intro-
duce Medi SPICE, which is currently under development and once completed may be used by medical 
device manufacturers as a method for accessing the capability of different software suppliers in rela-
tion to developing software using regulatory compliant software processes. 
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3 IEC 62304 – Software Lifecycle Processes 
Medical device manufactures wishing to achieve regulatory conformance are advised to follow the 
relevant applicable standards. Evidence of following the applicable standards can improve the process 
of achieving regulatory conformance. 
3.1 Processes  
IEC 62304 is a medical device software development lifecycle process standard. It was created to 
provide assistance in terms of the safe design and maintenance of medical device software. Software 
developed that adheres to IEC 62304 activities and tasks  is founded upon the assumption that the 
software is developed in accordance with a quality management standard (e.g. ISO 13485), a risk 
management standard (ISO 14971) and a product level standard (EN 60601-1). This standard pro-
vides a framework of processes divided into activities which are further divided into tasks.  
IEC 62304 provides guidance on the development of software as part of a medical device. 
However, IEC 62304 does not provide guidance on all of the necessary processes required to develop 
standalone software as an active medical device. IEC 62304 states: 
“This standard does not cover validation and final release of the medical device, even when the medi-
cal device consists entirely of software” 
With the MDD revision a medical device can consist only of software. As validation is required to en-
sure reliability and safety another method of validating standalone software as a medical device is 
required. In relation to this an international joint working standards group IEC TC62A JWG 7 has been 
created with members from both the medical device and software standards communities to develop a 
new standard IEC 82304 for Healthcare Software. IEC 82304 will treat standalone software as a com-
plete system. IEC 62304 is currently under revision and the developers of Medi SPICE [29] are work-
ing towards providing the Medi SPICE process reference model as an annex within the revision of IEC 
62304. 
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3.2 Safety Classification 
IEC 62304 classifies medical device software based on the risk posed to the patient or user. The de-
vices are classified as follows: 
 
¾ Class A: No injury or damage to health is possible; 
¾ Class B: Non-serious injury is possible; 
¾ Class C: Death or Serious Injury is possible. 
 
This classification is similar to that of ISO 14971 Clauses 4.4, 5 and 6.1. Safety critical software sys-
tems can be divided into items running a different software element each with its own safety classifica-
tion. These items can be further sub-divided into additional software elements. The overall software 
system assumes the highest classification contained within all of the software elements. For example, 
if a software system contains five software elements, four of which may be classified as Class A, but 
one may be classified as Class C then the overall device receives a classification of Class C. This can 
be seen in figure 1.   
Figure 1 Classification of software items within complete software system 
However, IEC 62304 makes provision for a software item to be segregated from the overall software 
system. This allows for the segregated software item to independently receive a lower safety classifi-
cation. 
4 Software Process Improvement and Medi SPICE  
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Software Process Improvement is an important element within any software development lifecycle. 
Many organisations have difficulty in consistently developing high quality software. There are many 
benefits to be gained by using SPI including [30]: 
 
¾ Improvements to overall quality; 
¾ Increased on-time delivery; 
¾ Budget consistency; 
¾ Reduced development costs. 
 
4.1 Importance of SPI 
SPI places the emphasis on defining processes that are appropriate to the project and ensures that 
these processes are consistently followed. SPI maturity models focus on what has to be done, rather 
than how it should be done. The benefits of utilising SPI can be seen in many companies e.g. Sie-
mens [31], Alcatel [32], NASA [33] and Motorola [34]. 
 In order for SPI to be successful within an organisation, it relies on a number of critical factors. 
In 2005 a survey of one hundred and twenty software organisations identified six organisational fac-
tors as being crucial to ensure the success of SPI [35]: 
 
¾ Business orientation; 
¾ Involved leadership; 
¾ Employee participation; 
¾ Concern for measurement; 
¾ Exploitation of existing knowledge; 
¾ Exploration of new knowledge. 
 
Research carried out by Embedded Market Forecasters in 2010 [36]  provided a comparison between 
software developed by the embedded industry and software developed by medical device producers. 
This research showed that 12.9% of medical device projects were cancelled, whilst 11.2% of embed-
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ded industry projects were cancelled. This research also revealed that on average 19.4% of the over-
all budget is wasted due to months lost during project development. The primary reason cited for the-
se problems occurring is incomplete or vague requirements.  
 An empirical study in 2007 revealed  how much importance medical device software develop-
ment companies place upon SPI [37]. The study surveyed organisations developing software for med-
ical devices and medical information systems with the majority of respondents coming from Germany, 
USA and Sweden. Seventy-one percent of respondents came from small and medium companies with 
between ten and two hundred & fifty employees. The remainder of the respondents came from organi-
sations with over two hundred & fifty developers. With ninety-eight percent rating software as either an 
important or very important part of their products. However, only fourteen percent had a CMMI (Capa-
bility Maturity Model Integration) or ISO 15504 (SPICE) rating. This survey also asked participant’s 
which process or activities cause the most issues for a software development project.  
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Figure 2 Activities & Processes most difficult to software development projects [37] 
Figure 2 shows that the Requirements Engineering process is seen as causing problems in the majori-
ty of medical device software development. Denger’s [37] research reveals that organisations typically 
following a defined set of processes or activities contained within an SPI model will have minimal prob-
lems with areas such as requirements engineering as they are provided guidance on all areas of de-
velopment. This survey shows an inversely proportional relationship between importance placed on 
SPI rating/activities and difficulties caused by specific process areas. 
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4.2 Medi SPICE  
Medical device software development companies face requirements and  difficulties not faced by de-
velopers of traditional software [38]. A primary requirement for medical device software development 
companies is the achievement of regulatory conformance. This is essential as organizations must 
achieve compliance and approval by the regulatory body of the country where they wish to market 
their medical device.  Current SPI models such as CMMI and SPICE were developed for generic soft-
ware development and therefore were not designed to provide sufficient coverage of all of the neces-
sary areas needed in order to achieve medical device regulatory approval.  The  is recognized  by a 
comparison made by Walker [39] between CMMI and the medical device regulations which states that 
CMMI can be used, but there is a requirement for  amended and extended processes to be put in 
place to meet the specific requirements of this domain. Similarly Burton et al [40] and McCaffery and 
Dorling [41] have each identified that existing SPI models can be used in the development of medical 
device software, however, these models  do not provide sufficient guidance in key development areas 
such as risk management and need to be amended and extended. Each of these studies also identify  
the need for a single point of reference which medical device software development companies can 
follow when developing medical device software. To address this requirement extensive research was 
undertaken [42] and as a result Medi SPICE [29] is currently under development by the Regulated 
Software Research Group (RSRG) at Dundalk Institute of Technology (DkIT) in collaboration with the 
SPICE User Group. The objective of Medi SPICE is to provide a framework which facilitates the im-
plementation of high quality medical device software processes that will enable seamless conformity 
to the medical regulatory standards.  This approach is in line with  the development of a domain spe-
cific SPI model for the automotive industry - Automotive SPICE [43]. 
Medi SPICE aims to minimise the volume of software documentation and provide global har-
monisation for all medical device software manufactures. The results of a Medi SPICE assessment 
may be used to indicate the current state of a medical device supplier’s software development practic-
es in relation to regulatory expectations. Therefore, the results of a Medi SPICE assessment may also 
be used as a criterion for medical device software supplier selection. This is particularly relevant with 
regard to the amendment’s requirement that manufactures should demonstrate that adequate controls 
have been put in place to ensure the supplier is fully utilising a quality management system. Medi 
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SPICE will also address the specific requirements of designing and developing medical device soft-
ware in a globally distributed environment [44, 45] 
4.2.1 Medi SPICE Structure 
Medi SPICE is being developed in line with the requirements of ISO/IEC 15504-2:2003 [46] and incor-
porates the requirements of IEC 62034 and the other relevant medical device regulations, standards 
and guidance documents.  Medi SPICE contains a Process Reference Model (PRM) and a Process 
Assessment Model (PAM). Medi SPICE consists of forty-three processes and twelve sub-processes 
each of these processes contain a process purpose, a number of outcomes and a number of specific 
practices that will have to be performed in order to fulfil the outcomes. The performance of the specific 
practices provides an indication as to the extent of achievement of the process purpose and out-
comes. Work products which are either used, produced or both, when performing the process are also 
recorded. The composition of the Medi SPICE processes is illustrated in figure 3. 
 
 
X- ISO/IEC 15504-5 Practices that are not mandatory for regulatory com-
pliance. 
Y- ISO/IEC 15504-5 Practices that are required for regulatory compliance. 
Z- Non-ISO/IEC 15504-5 Practices that are required for regulatory compli-
ance. 
 
Figure 3 Composition of Medi SPICE processes [41] 
 
4.2.2 Process Reference Model 
Given the importance of conformance to the latest standards the decision was taken to develop the 
Medi SPICE PRM in line with ISO/IEC 12207:2008 [47] and the next release of ISO/IEC 15504-5 (cur-
rently under ballot).  The first step in the development of the Medi SPICE PRM was the selection of 
the relevant processes.  In order to achieve this objective two key requirements needed to be ad-
dressed:  
1) The selection of effective life cycle processes;  
2) The selection of processes that facilitate conformance to the necessary medical device regulation 
standards and guidance documents.   
X 
Y Z 
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 The structure of ISO/IEC 12207:2008, and the next release of ISO/IEC 15504-5 were both 
reviewed in detail. Extensive analysis of the relevant medical device regulations and standards were 
undertaken.  Based on this work forty-three Medi SPICE processes and twelve sub-processes were 
identified and defined. These were then released for review by interested parties from the SPICE User 
Group and industry experts. Following their approval the Medi SPICE PRM was structured as follows:  
• The System Life Cycle Processes contains: 
  o  3 Agreement Processes and 7 Sub-processes; 
  o  6 Organizational Project - Enabling Processes and 6 Sub-processes; 
  o  7 Project Processes; 
  o  10 Technical Processes and 2 Sub-processes.   
• The Software Life Cycle Processes contains: 
  o  6 Software Implementation Processes; 
  o  9 Software Support Processes;  
  o  1 Supplementary Process.  
 
Having defined the processes and structure of the PRM the developers of Medi SPICE were invited to 
participate in the current revision of IEC 62304, to both assist with the alignment of IEC 62304 with 
ISO/IEC 12207:2008 and also to provide details to the medical device software development commu-
nity of the relationship between IEC 62304 and other medical device standards and guidelines. 
 Work has commenced on the development of the contents of the Medi SPICE PRM process-
es. The initial focus was on the IEC 62304 relevant processes. In line with the requirements of ISO 
15504-2 each process was assigned an ID and name, with a process purpose also being defined.  
Based on the process purpose, outcomes were identified. The purpose and outcomes addressed the 
requirements for an effective process and those of the medical device standards and regulations.  The 
regulatory aspects were addressed by undertaking a detailed analysis of the relevant standards and 
guidance documents with reference to each process. The Medi SPICE PRM in addition to the normal 
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relevant an outcome is given a safety classification (if the source of the outcome is IEC 62304). 
 The sixteen processes which constitute the subset of the Medi SPICE PRM for inclusion in the 
next release of IEC 62304 have been completed.  These are currently being reviewed by interested 
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parties from the SPICE User Group, industry experts and the IEC SC62A JWG3 Standards working 
group (the IEC 62304 development team). It is planned that this subset of the Medi SPICE PRM will 
be included in the Appendix of the forthcoming release of IEC 62304. The development of the remain-
ing Medi SPICE PRM processes is currently under way. 
4.2.3 Process Assessment Model 
The Medi SPICE PAM is also structured in line with ISO/IEC 12207:2008 and the next release of 
ISO/IEC 15504-5 (currently under ballot). The PAM is related to the Medi SPICE PRM and forms the 
basis for collecting evidence and the rating of process capability. This is achieved by the provision of a 
two-dimensional view of process capability. In one dimension, it describes a set of process specific 
practices that allow the achievement of the process outcomes defined in the PRM; this is termed the 
process dimension.  
In the other dimension, the PAM describes capabilities that relate to the process capability 
levels and process attributes, this is termed the capability dimension. Process attributes are used to 
determine whether a process has reached a given capability. Each attribute measures a particular 
aspect of the process capability    Indicators for process capability are generic practices that are appli-
cable to any process and are associated with process attributes, generic work products and generic 
resources that can be observed when a particular process attribute is achieved. In line with ISO/IE 
15504-2 the Medi SPICE process capability is defined over 6 levels:  
 
• Level 0 Incomplete; 
• Level 1 Performed; 
• Level 2 Managed; 
• Level 3 Established; 
• Level 4 Predictable; 
• Level 5 Optimizing. 
4.2.4 Medi SPICE Validation 
The Medi SPICE PRM and PAM are being released in stages and each stage is extensively reviewed 
and validated prior to release.  A key aspect of the development of Medi SPICE is that it is being un-
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dertaken in a collaborative manner and input and approval are sought from interested parties in the 
SPICE User Group, international standards bodies and representatives from the medical device soft-
ware industry.  In this way we ensure that each release of the Medi SPICE PRM and PAM are validat-
ed by both the SPI community and industry experts.   
 In addition we have also developed and successfully implemented a lightweight medical de-
vice software process centric assessment model with the objective of validating key aspects of Medi 
SPICE.  Known as Medi SPICE Adept [48] this method currently enables the assessment of ten Medi 
SPICE processes, although it will be extended to include all Medi SPICE processes whenever they 
have been fully developed. It allows organizations to have each of these processes assessed regard-
ing their conformance to the specific requirements of the medical device regulations, standards, and 
guidance documents. It also provides a method for carrying out an assessment against the require-
ments for best software engineering practice. The successful implementation of this method has al-
lowed key aspects of Medi SPICE to be tested and validated in an industrial setting. It has also pro-
vided relevant feedback which has been documented and incorporated into the on-going development 
of the Medi SPICE.  Based on this work future releases of Medi SPICE will be trialled and validated in 
an industrial setting. 
5 Conclusions 
The recent revision to the MDD allows for standalone software to be an active medical device and  
states that software must be validated in accordance with state of the art practices. This paper focuses 
on changes as part of the MDD which have a direct impact on the development of medical device 
software. The most significant change as part of this recent amendment was that standalone software 
previously exempt from regulatory control now falls under the umbrella of requiring regulatory approv-
al. To accompany this, recommendations are made as to how medical device software development 
companies can conform to the latest regulatory requirements by utilising SPI models such as Medi 
SPICE. 
Currently, no single point of reference is available  that provides medical device software de-
velopment companies guidance on end to end development of both embedded software and 
standalone software that conforms to the latest regulatory requirements. Existing standards only in-
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clude practices specific to themselves and practices in other standards are not included. For example, 
IEC 62304 does not currently address the systems aspect of software development and therefore 
does not address the requirements elicitation stage of development. IEC 62304 hands off these sys-
tem level processes to its aligned standards. However, research has shown that the requirements 
elicitation stage is the development phase which presents medical device software development com-
panies with the most issues [36, 37]. The authors of this paper are currently developing Medi SPICE to 
provide guidance for all stages of development of both embedded and standalone medical device 
software. Additionally, Medi SPICE will provide a single source for obtaining all medical device regula-
tory requirements. The development of Medi SPICE is on-going, but it has been piloted in a number of 
Irish and Australian organisations using a lightweight software process assessment method Medi 
SPICE Adept [48].  
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